XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Summary of Significant Accounting Policies - Revenue by Type (Details) - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Total revenue $ 299.8 $ 678.4 $ 690.6 $ 638.6
Testing revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 279.6 678.4 666.4 586.9
Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 159.3 305.5 316.3 347.4
Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 33.9 128.6 120.9 48.3
Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 37.6 116.4 106.8 76.7
Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 29.8 127.6 93.7 74.1
Autoimmune        
Disaggregation of Revenue [Line Items]        
Total revenue 18.0 0.3 28.2 39.1
Other        
Disaggregation of Revenue [Line Items]        
Total revenue 1.0 0.0 0.5 1.3
Other revenue        
Disaggregation of Revenue [Line Items]        
Total revenue $ 20.2 $ 0.0 $ 24.2 $ 51.7